Stockscreener 앱 받기
0.7151
2.30%
0.0161
시간 외 거래:
.70
-0.0151
-2.11%
전일 마감가:
$0.699
열려 있는:
$0.68
하루 거래량:
2.04M
Relative Volume:
2.45
시가총액:
$2.17M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.78%
1개월 성능:
-50.17%
6개월 성능:
-92.33%
1년 성능:
-99.63%
1일 변동 폭
$0.68
$0.89
1주일 범위
$0.65
$0.89
52주 변동 폭
$0.65
$213.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
명칭
Cero Therapeutics Holdings Inc
전화
650-407-2376
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
CERO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.7151 | 2.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
CERo Therapeutics Delays Yearly Report Filing - TipRanks
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors - Nasdaq
CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors - MarketScreener
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors - The Manila Times
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of - GlobeNewswire
Groundbreaking CAR-T Cancer Therapy Advances: FDA Greenlights Dual-Action Trial - Stock Titan
CERo Therapeutics gears up for clinical trial of cancer therapy By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges - Investing.com Australia
CERo Therapeutics gears up for clinical trial of cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Poised to Initiate - GlobeNewswire
FDA Green Light: CERo's Leukemia Drug CER-1236 Advances to Human Trials with Optimized Manufacturing - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Trading 4.6% Higher – Here’s What Happened - Defense World
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish - NewsBreak: Local News & Alerts
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Ca - Asianet Newsable
CERO Flat on Leukemia Drug Developments - Baystreet.ca
CERo Therapeutics partners with UC Davis for AML trial By Investing.com - Investing.com South Africa
CERo Therapeutics partners with UC Davis for AML trial - Investing.com
Restaurant Brands International to Report First Quarter 2025 Results on May 8, 2025 - The Globe and Mail
CERo Therapeutics Announces Manufacturing Agreement with UC Davis Ahead of Phase 1 Clinical Trial for AML - Nasdaq
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study By Investing.com - Investing.com Australia
CERo Therapeutics reports positive preclinical results for cancer treatment By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Understanding CERO’s financial ratios: A beginner’s guide - US Post News
CERo Therapeutics Holdings, Inc. Presents Encouraging - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study - Investing.com
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - The Manila Times
Looking for Exposure to NFLX? Try These Two ETFs - The Globe and Mail
CERo Therapeutics reports positive preclinical results for cancer treatment - Investing.com India
CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation - Nasdaq
Breakthrough: CERo's Novel Cancer Treatment Targets Ovarian Cancer With Zero Toxicity - StockTitan
CERO stock plunges to 52-week low at $1.31 amid market challenges - Investing.com Australia
CERO stock plunges to 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
CERo Therapeutics Holdings, Inc. Announces Progress in - GlobeNewswire
Will This New AML Treatment Strategy Transform Blood Cancer Therapy? CERo Takes Critical Step - StockTitan
CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference - Nasdaq
CERo Therapeutics Holdings, Inc. to Present Data at the - GlobeNewswire
Can CERo's Cancer-Fighting T Cells Transform Ovarian Cancer Treatment? New Data Coming March - StockTitan
3 Companies Buying Back Stock – Why They’re Doubling Down - The Globe and Mail
CERO stock touches 52-week low at $1.52 amid market challenges - Investing.com Canada
CERO stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
Cero Therapeutics Holdings Inc (CERO) 재무 분석
Cero Therapeutics Holdings Inc (CERO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):